Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942368 · ClinicalTrials.gov registry record · NA
Adaptive tDCS for Treatment-Resistant MDD
A NA study of Depressive Disorder, Treatment-Resistant, sponsored by Washington University School of Medicine.
- Active
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02942368: Active NA study of Depressive Disorder, Treatment-Resistant, sponsored by Washington University School of Medicine.
NCT02942368 is a NA study of Depressive Disorder, Treatment-Resistant that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 25 participants, below the 235-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942368, a NA study of Depressive Disorder, Treatment-Resistant, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD). tDCS is a noninvasive brain stimulation technique which has been utilized for the treatment of major depression in several studies, both as a primary and adjunctive treatment. The treatment will be administered under the supervision of a physician with experience in administering the treatment and monitoring for complications. This will be a prospective "adaptive tDCS stimulation" open label research study. Participants will receive 20 minute sessions of up to 4 milliamps (mA) transcutaneous electrical stimulation sessions over 4 to 6 weeks. Building on the theory that greater current "dose" may be a significant factor in determining efficacy, this study aims to determine whether higher tDCS current doses lead to greater improvements in depressive symptoms in this population of patients with treatment-resistant major depressive disorder.
Conditions Studied
Interventions
- DEVICE tDCS
Study Locations (1)
Missouri
- Washington University in Saint Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-04-14 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT02942368 still lists
NCT02942368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 235-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Depressive Disorder, Treatment-Resistant appearing as the primary indexed condition, and to 1 intervention - of which tDCS is the first listed.
NCT02942368 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02942368 about?
NCT02942368 is a clinical study titled "Adaptive tDCS for Treatment-Resistant MDD". This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD). tDCS is a noninvasive brain stimulation technique which has been utilized for the treatment of major depression in severa...
What is the current status of trial NCT02942368?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2017-04-14. Estimated completion is 2027-12.
What conditions does trial NCT02942368 study?
This clinical trial studies the following conditions: Depressive Disorder, Treatment-Resistant.
What interventions are being tested in trial NCT02942368?
The interventions under investigation include: tDCS (DEVICE).
Who is sponsoring clinical trial NCT02942368?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02942368 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Treatment-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02942368's enrollment target sits among peer trials
25 10th of 9 the lowest of 9 other Depressive Disorder, Treatment-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Treatment-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
COMPLETED · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Intravenous Ketamine for Treatment-Resistant Depression
RECRUITING · Phase 2
-
Improving Brain Stimulation Through Imaging
ACTIVE NOT RECRUITING
-
Dopaminergic Dysfunction in Late-Life Depression
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI